v3.26.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jul. 03, 2026
Jan. 02, 2026
Current assets:    
Cash and cash equivalents $ 281,448 $ 482,488
Marketable securities 557,937 576,603
Trade receivables, net 322,213 286,916
Inventory 28,729 21,686
Prepaid expenses and other current assets 60,495 75,596
Total current assets 1,250,822 1,443,289
Non-current marketable securities 544,930 603,603
Property and equipment, net 92,665 98,960
Deferred tax assets, net 294,205 292,582
Goodwill 63,684 63,684
Right-of-use assets and other non-current assets 247,928 342,305
Total assets 2,494,234 2,844,423
Current liabilities:    
Accounts payable 39,062 29,623
Accrued compensation and benefits 68,629 102,218
Accrued clinical trial liabilities 59,767 65,742
Rebates and fees due to customers 66,711 59,896
Accrued collaboration liabilities 25,096 22,783
Other current liabilities 102,662 125,382
Total current liabilities 361,927 405,644
Non-current operating lease liabilities 165,929 173,038
Other non-current liabilities 122,616 104,422
Total liabilities 650,472 683,104
Commitments and contingencies (Note 11)
Stockholders’ equity:    
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued 0 0
Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 248,885 and 262,483 at June 30, 2026, and December 31, 2025, respectively 249 262
Additional paid-in-capital 2,108,059 2,234,411
Accumulated other comprehensive income (loss) (2,013) 3,476
Accumulated deficit (262,533) (76,830)
Total stockholders’ equity 1,843,762 2,161,319
Total liabilities and stockholders’ equity $ 2,494,234 $ 2,844,423